Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
The total study duration per participant was up to 28 months including an up to 28 days screening period, an up to 24 months treatment period, and a 3 months safety follow up period.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must had a known diagnosis of either metastatic castration-resistant prostate cancer (mCRPC) or non-small cell lung cancer (NSCLC) with evidence of measurable disease.
Failure of, inability to, or refusal to receive standard of care.
Greater than or equal to (\>=) 18 years of age.
You may not be if
Prior exposure to isatuximab or participation in clinical studies with isatuximab.
For participants with mCRPC, prior exposure to any agent (approved or investigational) that blocks the PD-1/PD-L1 pathway.
Evidence of other immune related disease /conditions.
History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.
Had received a live-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus were permitted.
Prior solid organ or hematologic transplant.
Eastern Cooperative Oncology Group performance status (PS) \>=2.
Poor bone marrow reserve.
Poor organ function.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Clareo Health | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
